{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"EP_0614977_B1","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"058-544-232-353-72X","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11813,"type":"PATENT","title":"University of Aberdeen Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":27926,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8443,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
Search Applicants and Owners separately: univ* aberdeen. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 1658
(a) evaluating the characteristics of huntingtin nucleic acid in a sample from the subject, wherein the evaluation comprises detecting the huntingtin (CAG)n region shown in SEQ ID NO:5 in the sample; and
(b) comparing the characteristics found in (a) with a similar analysis from an individual with no family history of Huntington's disease, where the nucleic acid has from 11 to 34 (CAG) repeats, the presence of, or predisposition to develop, Huntington's disease being indicated if those characteristics in the huntingtin (CAG)n region differ."],"number":10,"annotation":false,"claim":true,"title":false},{"lines":["A method according to claim 10, wherein the characteristics of huntingtin nucleic acid are evaluated by Southern blot, northern blot, or polymerase chain reaction analysis."],"number":11,"annotation":false,"claim":true,"title":false},{"lines":["The use of:
(a) a nucleic acid molecule according to claim 2, 3 or 4 or a vector according to claim 5 or claim 6;
(b) a polypeptide according to claim 1; and/or
(c) a host cell according to claim 7in the preparation of a medicament."],"number":12,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 12, wherein the medicament is for treating, delaying or preventing a neurodegenerative disorder."],"number":13,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 12 or claim 13, wherein the medicament is for gene therapy."],"number":14,"annotation":false,"claim":true,"title":false},{"lines":["The use according to claim 12, 13 or 14, wherein the medicament is for treating, preventing or delaying Huntingdon's disease."],"number":15,"annotation":false,"claim":true,"title":false},{"lines":["The use according to any of claims 12 to 15 wherein the nucleic acid has from 11 to 34 (CAG) repeats and/or the polypeptide has from 11 to 34 Gln repeats, said repeats being consecutive."],"number":16,"annotation":false,"claim":true,"title":false},{"lines":["A diagnostic and/or immunoassay kit comprising at least one container and;
(a) a nucleic acid molecule according to claim 2, 3 or 4, optionally labelled; or
(b) an antibody according to claim 8, optionally labelled."],"number":17,"annotation":false,"claim":true,"title":false},{"lines":["A pharmaceutical composition comprising:
(a) a nucleic acid molecule according to claim 2, 3 or 4 or a vector according to claim 5 or claim 6;
(b) a polypeptide according to claim 1; and/or
(c) a host cell according to claim 7 in admixture with pharmaceutically acceptable carrier."],"number":18,"annotation":false,"claim":true,"title":false},{"lines":["A process for the preparation of a polypeptide according to claim 1, the process comprising culturing a host cell according to claim 7 under conditions whereby the polypeptide is expressed, and purifying or isolating the polypeptide."],"number":19,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}